Published in PLoS One on February 24, 2011
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci (2012) 0.89
Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. ACS Chem Neurosci (2014) 0.85
Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential. Cell Biochem Biophys (2013) 0.81
A-kinase anchoring proteins: cAMP compartmentalization in neurodegenerative and obstructive pulmonary diseases. Br J Pharmacol (2014) 0.81
Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson's patients leukocytes. BMC Genomics (2013) 0.80
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. ACS Chem Neurosci (2012) 0.79
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. Br J Pharmacol (2015) 0.77
Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: role of C/EBPβ. J Neuroinflammation (2016) 0.75
Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair. Int J Mol Sci (2017) 0.75
Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. Stem Cells Transl Med (2015) 0.75
CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor. J Neuroinflammation (2015) 0.75
Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep (2017) 0.75
Emerging preclinical pharmacological targets for Parkinson's disease. Oncotarget (2016) 0.75
Function and regulation of CREB family transcription factors in the nervous system. Neuron (2002) 7.99
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev (2006) 6.75
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem (2007) 5.62
Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res (1970) 4.65
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 4.13
Disruption of CREB function in brain leads to neurodegeneration. Nat Genet (2002) 3.54
Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol (2003) 3.42
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci (2000) 2.75
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci (2006) 2.15
Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther (2000) 2.14
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol (2003) 2.14
Functional role of the nigro-neostriatal dopamine neurons. Acta Pharmacol Toxicol (Copenh) (1966) 2.13
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol (1996) 1.96
Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet (2000) 1.92
Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol (2005) 1.82
Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci (2002) 1.57
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Activity-dependent neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity, and temporal regulation of CREB phosphorylation at serine 133. J Neurosci (2005) 1.51
Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab (2001) 1.47
Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology (2010) 1.38
Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem (2005) 1.34
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J (2005) 1.30
Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol (2000) 1.29
The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol (2008) 1.26
Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci (2000) 1.25
Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet (2003) 1.22
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev (2005) 1.21
Microarray analysis supports a role for ccaat/enhancer-binding protein-beta in brain injury. J Biol Chem (2004) 1.21
The guanine nucleotide exchange factor CNrasGEF activates ras in response to cAMP and cGMP. Curr Biol (2000) 1.15
Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem (2006) 1.12
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. Proc Natl Acad Sci U S A (2010) 1.05
NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci U S A (2010) 1.05
NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci (2007) 1.00
CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury. J Cell Sci (2008) 0.99
Phosphodiesterases in the central nervous system. Handb Exp Pharmacol (2009) 0.94
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des (2006) 0.88
Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience (2005) 0.88
Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett (2008) 0.88
The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs (2007) 0.87
Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. ChemMedChem (2009) 0.87
Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol (2002) 0.86
Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J (2002) 0.85
Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse (2001) 0.84
Induction of neurite outgrowth in PC12 cells by the bacterial nucleoside N6-methyldeoxyadenosine is mediated through adenosine A2a receptors and via cAMP and MAPK signaling pathways. Biochem Biophys Res Commun (2003) 0.83
Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J Med Chem (2000) 0.81
Pituitary adenylate cyclase-activating polypeptide stimulates glial fibrillary acidic protein gene expression in cortical precursor cells by activating Ras and Rap1. Mol Cell Neurosci (2008) 0.81
Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J Neural Transm Gen Sect (1994) 0.81
CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem (2007) 0.80
Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease. Brain Res Bull (2002) 0.79
Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. J Neurosci Res (2009) 0.77
Organic azides: an exploding diversity of a unique class of compounds. Angew Chem Int Ed Engl (2005) 3.62
Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. Bioorg Med Chem (2007) 1.98
Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. J Am Soc Echocardiogr (2007) 1.64
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS (2009) 1.35
Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem (2005) 1.34
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr (2005) 1.33
Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod (2006) 1.25
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev (2005) 1.21
CCAAT/enhancer-binding protein beta plays a regulatory role in differentiation and apoptosis of neuroblastoma cells. J Biol Chem (2001) 1.12
Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev (2010) 1.09
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.08
The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. Bioorg Med Chem (2002) 1.03
The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. Biochem J (2003) 1.02
NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci (2007) 1.00
Bap, a biofilm matrix protein of Staphylococcus aureus prevents cellular internalization through binding to GP96 host receptor. PLoS Pathog (2012) 1.00
15-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis (2004) 0.99
CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury. J Cell Sci (2008) 0.99
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des (2006) 0.99
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene (2003) 0.97
Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo. Glia (2011) 0.97
Relative contributions of lipooligosaccharide inner and outer core modifications to nontypeable Haemophilus influenzae pathogenesis. Infect Immun (2013) 0.96
Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci (2012) 0.96
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep (2007) 0.96
Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorg Med Chem (2008) 0.94
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int J Alzheimers Dis (2011) 0.94
Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. J Immunol (2013) 0.93
β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. Environ Toxicol Pharmacol (2013) 0.92
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. J Med Chem (2011) 0.90
Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol Psychiatry (2012) 0.90
Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J Med Chem (2011) 0.89
Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. ChemMedChem (2009) 0.87
Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. BMC Public Health (2011) 0.86
Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8. PLoS One (2010) 0.86
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology (2012) 0.85
Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. ACS Chem Neurosci (2014) 0.85
A dual role for the dREAM/MMB complex in the regulation of differentiation-specific E2F/RB target genes. Mol Cell Biol (2012) 0.85
Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging (2013) 0.85
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem (2012) 0.84
The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS (2007) 0.84
Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. Curr Top Med Chem (2013) 0.83
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem (2011) 0.83
The RCPCH care pathway for food allergy in children: an evidence and consensus based national approach. Arch Dis Child (2011) 0.83
Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2. Breast Cancer Res Treat (2010) 0.82
Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. Bioorg Med Chem (2005) 0.82
Role of C/EBPβ transcription factor in adult hippocampal neurogenesis. PLoS One (2011) 0.82
PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS One (2011) 0.82
The spot 14 protein inhibits growth and induces differentiation and cell death of human MCF-7 breast cancer cells. Biochem J (2005) 0.82
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem (2012) 0.82
Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr (2004) 0.82
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorg Med Chem (2008) 0.81
Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem (2009) 0.81
Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J Med Chem (2003) 0.81
A novel BRCA1 mutation in a Spanish patient with ovarian cancer. Breast Cancer Res Treat (2008) 0.80
Hypothyroidism decreases the biogenesis in free mitochondria and neuronal oxygen consumption in the cerebral cortex of developing rats. Endocrinology (2009) 0.80
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem (2014) 0.80
cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat (2014) 0.80
CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem (2007) 0.80
Factors associated to duration of hepatitis a outbreaks: implications for control. PLoS One (2012) 0.80